228 related articles for article (PubMed ID: 11929336)
1. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
Jacobsohn DA; Vogelsang GB
Drugs; 2002; 62(6):879-89. PubMed ID: 11929336
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutics for the treatment of graft-versus-host disease.
Jacobsohn DA
Expert Opin Investig Drugs; 2002 Sep; 11(9):1271-80. PubMed ID: 12225248
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for graft-versus-host disease.
Jacobsohn DA
Expert Opin Emerg Drugs; 2003 Nov; 8(2):323-38. PubMed ID: 14661992
[TBL] [Abstract][Full Text] [Related]
4. New developments in the prophylaxis and treatment of graft versus host disease.
Simpson D
Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062
[TBL] [Abstract][Full Text] [Related]
5. Anti-cytokine therapy for the treatment of graft-versus-host disease.
Jacobsohn DA; Vogelsang GB
Curr Pharm Des; 2004; 10(11):1195-205. PubMed ID: 15078135
[TBL] [Abstract][Full Text] [Related]
6. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.
Rodriguez V; Anderson PM; Trotz BA; Arndt CA; Allen JA; Khan SP
Pediatr Blood Cancer; 2007 Aug; 49(2):212-5. PubMed ID: 16261610
[TBL] [Abstract][Full Text] [Related]
7. Steroid-refractory graft-vs.-host disease: past, present and future.
Carpenter PA; Sanders JE
Pediatr Transplant; 2003; 7 Suppl 3():19-31. PubMed ID: 12603689
[TBL] [Abstract][Full Text] [Related]
8. Management of graft-versus-host disease.
Arai S; Vogelsang GB
Blood Rev; 2000 Dec; 14(4):190-204. PubMed ID: 11124107
[TBL] [Abstract][Full Text] [Related]
9. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
10. New immunosuppressants in BMT/GVHD.
Basara N; Günzelmann S; Willenbacher W; Fauser AA; Kiehl MG
Transplant Proc; 2001 May; 33(3):2220-2. PubMed ID: 11377507
[No Abstract] [Full Text] [Related]
11. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
12. [Role of monoclonal antibodies in the treatment of acute graft versus host disease].
Bay JO; Cabrespine A; Peffault de Latour R
Bull Cancer; 2007 Jan; 94(1):33-41. PubMed ID: 17237003
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive drugs in paediatric liver transplantation.
van Mourik ID; Kelly DA
Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.
Rager A; Frey N; Goldstein SC; Reshef R; Hexner EO; Loren A; Luger SM; Perl A; Tsai D; Davis J; Vozniak M; Smith J; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2011 Mar; 46(3):430-5. PubMed ID: 20498647
[TBL] [Abstract][Full Text] [Related]
15. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
Joyal D; Cantarovich M; Cecere R; Giannetti N
Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
[TBL] [Abstract][Full Text] [Related]
16. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
Xhaard A; Hermet E; Bay JO; Peffault de Latour R
Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy for acute graft-versus-host disease prophylaxis.
Simpson D
J Hematother Stem Cell Res; 2000 Jun; 9(3):317-25. PubMed ID: 10894353
[TBL] [Abstract][Full Text] [Related]
18. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
19. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab.
Willenbacher W; Basara N; Blau IW; Fauser AA; Kiehl MG
Br J Haematol; 2001 Mar; 112(3):820-3. PubMed ID: 11260089
[TBL] [Abstract][Full Text] [Related]
20. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
